South Dakota 2022 Regular Session

South Dakota Senate Bill SB22

Introduced
1/11/22  
Refer
1/11/22  
Report Pass
1/25/22  
Engrossed
1/26/22  
Refer
2/15/22  
Report Pass
2/25/22  
Enrolled
2/28/22  

Caption

Revise a reference to the Division of Criminal Investigation.

Impact

If implemented, SB22 would provide a clearer mandate for the Division of Criminal Investigation, specifically in matters related to medical cannabis. With the formation of the oversight committee, the bill intends to facilitate better communication and cooperation among multiple stakeholders, which could help establish more effective policies regarding medical cannabis use and regulation in South Dakota. By appointing qualified individuals to the committee, the bill emphasizes a nuanced approach to policy development that considers the diverse experiences and perspectives of those affected by cannabis legislation.

Summary

Senate Bill 22 seeks to revise references to the Division of Criminal Investigation within state law, particularly in the context of overseeing medical cannabis operations. The bill aims to enhance the structure and functionality of oversight by establishing a committee comprising various stakeholders, including law enforcement representatives, legal professionals, and individuals with experience in medical cannabis. This bill is significant for its role in creating an organized framework for the regulation and implementation of cannabis-related policies, ensuring that all parties involved have a voice in the development of these regulations.

Sentiment

The sentiment surrounding SB22 appeared generally positive, particularly among those advocating for a well-structured approach to medical cannabis regulation. Supporters believe that the establishment of an oversight committee will lead to more informed and effective regulations, bringing legitimacy to the state's cannabis industry. However, opinions varied in the context of concerns regarding the thoroughness of oversight and the extent of power delegated to the committee, highlighting a need for ongoing dialogue about the exact roles and responsibilities of committee members.

Contention

Notable points of contention stemmed from concerns about the potential for bureaucratic overreach and the need for accountability within the oversight committee. Opponents raised questions about how effective the committee would be in addressing the needs of patients and the medical cannabis community, considering the diverse interests of members appointed. Furthermore, critics questioned whether the restructuring would adequately protect against any misuse of power by law enforcement or other committee members, emphasizing the importance of maintaining transparency and community engagement in discussions about cannabis policy.

Companion Bills

No companion bills found.

Previously Filed As

SD SB134

Revise membership of the Medical Marijuana Oversight Committee.

SD SB23

Revise the definition of bona fide practitioner-patient relationship.

SD SB274

State Auditor; powers and duties revised; Division of Investigations created

SD HB485

State Auditor; powers and duties revised; Division of Investigations created

SD HB1056

Revise provisions related to medical cannabis data maintained by the Department of Health.

SD HB562

State Auditor; powers and duties revised; Division of Investigations created

SD SB163

State Auditor; powers and duties revised; Division of Investigations created

SD HB1175

Update references to the Governor, lieutenant governor, and other persons.

SD HB1010

Revise certain references to the Internal Revenue Code.

SD SB12

Revise the annual report on medical cannabis by the Department of Health to the Legislature.

Similar Bills

No similar bills found.